A previous study presented that
glycyrrhizic acid as the hepatoprotective agent inhibits
total parenteral nutrition-associated acute liver injury in rats. However, the anticancer effect and mechanism of
glycyrrhizic acid in human
hepatocellular carcinoma (HCC) is ambiguous. The purpose of the present study was to investigate the effect of
glycyrrhizic acid on apoptosis dysregulation and metastatic potential in HCC in vitro and in vivo. Both SK-Hep1 and Hep3B cells were treated with different concentrations of
glycyrrhizic acid for 24 or 48h. SK-Hep1/luc2
tumor-bearing mice were treated with vehicle or
glycyrrhizic acid (50mg/kg/day by
intraperitoneal injection) for 7 days.
Tumor cells growth, apoptotic, and metastatic signaling transduction were evaluated by using MTT assay, digital caliper, bioluminescence imaging (BLI), flow cytometry, western blotting assay, and immunohistochemistry (IHC) staining. The results demonstrated
glycyrrhizic acid significantly inhibits
tumor cell growth, cell invasion, and expression of AKT (Ser473),
extracellular-signal-regulated kinase (ERK),
epidermal growth factor receptor (EGFR) phosphorylation, anti-apoptotic and metastatic
proteins in HCC in vitro and in vivo.
Glycyrrhizic acid also significantly triggered apoptosis and extrinsic/intrinsic apoptotic signaling transduction. In addition,
PD98059 (ERK inhibitor) and
LY294002 (AKT inhibitor) obviously reduced cell invasion and expression of
metastasis-associated
proteins. Taken together, these results indicated that
glycyrrhizic acid induces apoptosis through extrinsic/intrinsic apoptotic signaling pathways and diminishes EGFR/AKT/ERK-modulated metastatic potential in HCC in vitro and in vivo.